Q-linea: US progress - Redeye

The NTAP reimbursement decision is distinctly positive, and the CMS decision enables clinics to use the three-year NTAP reimbursement rate of USD 97.50 per patient (a typical patient will require one test per admission) as of 1 October 2024. As a result, Q-linea’s ability to extend the US pipeline of clinical ASTar evaluations will become a more important value driver, and Q-linea’s prospects of securing US commercial partners are now improved.

Länk till analysen i sin helhet: https://www.redeye.se/research/1037352/q-linea-us-progress?utm_source=finwire&utm_medium=RSS